Navigation Links
Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
Date:9/9/2008

HAYWARD, Calif., Sept. 9 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the appointment of Kenneth Luskey, M.D. to the newly created position of Vice President, Clinical Research reporting to K. Alice Leung, the Company's CEO. In his new role, Dr. Luskey will lead the clinical development of Intarcia's proprietary drug development programs including Omega DUROS(R) therapy for hepatitis C and ITCA 650 for the treatment of type 2 diabetes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

Dr. Luskey has extensive experience in endocrinology and metabolism research, as well as in drug development. He spent more than 13 years in academic medicine prior to holding leadership positions with several biopharmaceutical companies where he directed the development of new therapies for the treatment of diabetes. Dr. Luskey began his career at the National Institutes of Health before completing a fellowship and receiving a faculty appointment at the University of Texas Southwestern Medical School. While in Dallas, he worked extensively with Drs. Joseph L. Goldstein and Michael Brown, winners of the Nobel Prize in Medicine in 1985 for their work on cholesterol metabolism. In 1991, Dr. Luskey joined Scios, Inc. (now a member of the Johnson & Johnson family of companies) where he led research efforts to develop new treatments for diabetes and obesity. Subsequently, Dr. Luskey joined Metabolex, Inc. where he led research and drug development programs focused on diabetes and impaired glucose tolerance as Vice President, Clinical Development. Dr. Luskey also was head of experimental medicine for Tularik Inc. (subsequently acquired by Amgen Inc.), and was most recently head of preclinical and translational medicine for Nuvelo, Inc. Dr. Luskey received his medical education at the University of Texas Southwestern Medical School in Dallas. He trained in in
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Announces Reverse Stock Split
2. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
3. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
4. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
5. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
6. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
7. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
8. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
9. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
10. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
11. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... August 22, 2014 Ophthalmic drug ... interesting and challenging endeavors as the anatomy, physiology ... properties to the foreign substances. Ocular drug delivery ... self medication and minimal use of needles; also ... drugs and provides specific targeting within the ocular ...
(Date:8/22/2014)... Research and Markets has announced the addition ... Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - ... The global molecular biology enzymes market was ... to grow at a CAGR of 13.74% to reach ... reagents find applications in a large number of fields ...
(Date:8/22/2014)... Toronto, Canada (PRWEB) August 22, 2014 ... traits in model organisms can be accelerated by ... design and manufacturing technologies, the custom SeqCap EZ ... such research. , Mr. Watson will additionally present ... seen with commercially available human and mouse exome ...
(Date:8/21/2014)... Rockville, MD (PRWEB) August 21, 2014 ... is making progress in its development of JRC-LAMP-vax, an ... red cedar pollen. Phase IC studies began this month ... solution to hay fever. , The Japanese red cedar ... million people in Japan. Mountain Cedar pollen wreaks similar ...
Breaking Biology Technology:Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4
... Hemobag(R) prevents wastage by saving the patient,s own whole ... paper in a journal for,perfusionists, the health professionals who ... heart surgery, reports how Global Blood,Resources, online waste calculator ... seen with the "cell washing" machines most commonly used,during ...
... -- Using artificial sugar and some clever chemistry, University ... internal light comes from the sugar coating on their ... sugar chains, or carbohydrates, that coat cells is a ... a laboratory organism popular because its transparent embryos allow ...
... 5 VION PHARMACEUTICALS,INC. (Nasdaq: VION ) today ... 2008., The Company reported a net loss of ... ended March 31, 2008, compared with a net loss,of ... period in 2007.,Weighted-average common shares outstanding for the three ...
Cached Biology Technology:Global Blood Resources' On-Line Calculator Reveals Wasted Blood Costs by Blood Salvage Machines During Heart Surgery to be in the Billions 2Global Blood Resources' On-Line Calculator Reveals Wasted Blood Costs by Blood Salvage Machines During Heart Surgery to be in the Billions 3Glowing zebrafish help researchers track role of sugars in the cell 2Glowing zebrafish help researchers track role of sugars in the cell 3Vion Reports 2008 First Quarter Results 2Vion Reports 2008 First Quarter Results 3Vion Reports 2008 First Quarter Results 4
(Date:8/22/2014)... available in German . ... PCFs proteins are fixated in a way so as ... the HZB and Fudan University researchers are planning on ... materials. Their findings are being published today in the ... Proteins are sensitive molecules. Everyone knows that at ...
(Date:8/22/2014)... to purchase fuel cell cars from Toyota and other ... cars will run on hydrogen made from natural gas, ... Now scientists at Stanford University have developed a low-cost, ... produce hydrogen by water electrolysis. The battery sends ... water into hydrogen and oxygen gas. Unlike other water ...
(Date:8/21/2014)... new study of American singles found that during ... highest orgasm rates. On average, men experience orgasm ... orientation making little difference. For women, however, orgasm ... orgasm 62.9 percent of the time during sex ... varies with women,s sexual orientation, with lesbian women ...
Breaking Biology News(10 mins):Proteins: New class of materials discovered 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4
... of the brain and spine in America,s babies, particularly those of Hispanic origin, ... the B vitamin folic acid, according to a new petition filed with the ... Gruma Corporation Spina Bifida ... of Dimes Foundation , ...
... perennially covered in ice. It is exposed to severe ... and, during the winter, 24-hour darkness. But, for the ... To study them, Dr. Rachel Morgan-Kiss from the University ... to sample the ice-covered lake. The article describing her ...
... Academy at the University of Gothenburg, Sweden, have ... osteoporosis. The study, published in Nature Genetics ... shows among other interesting facts that women with a ... a more than 50 percent increased fracture risk. ...
Cached Biology News:Coalition petitions FDA to fortify corn masa flour with folic acid 2Coalition petitions FDA to fortify corn masa flour with folic acid 3Research on carbon-consuming life-forms in Antarctica published in JoVE 2Scientists have discovered genes that increase the risk of osteoporosis and fractures 2
One-step, microplate or cuvet, turbidometric, linear detection range 0.096 mg/dL to 11.5 mg/dL. Procedure: 5 min....
One-step, microplate or cuvet, colorimetric, detection range 0.1 mg/dL to 3 mg/dL. Procedure: 10 min....
Moue Serum 8-12 Weeks Old...
Request Info...
Biology Products: